Leqembi Iqlik PDUFA Date Extended
Analysis based on 14 articles · First reported May 08, 2026 · Last updated May 09, 2026
The extension of the United States — Food and Drug Administration's review period for Lecanemab Iqlik's sBLA by three months is a negative development for Eisai and BioArctic, as it delays the potential market entry of a new dosing regimen for Lecanemab. This could lead to a temporary dip in investor confidence for both companies, impacting their stock prices.
The United States — Food and Drug Administration has extended the review period for Eisai's supplemental Biologics License Application (sBLA) for Lecanemab Iqlik, a once-weekly subcutaneous injection of lecanemab irmb for early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is now August 24, 2026, a three-month extension from the previous May 24, 2026, date. This extension was due to the United States — Food and Drug Administration requesting additional information, which constituted a major amendment to the sBLA. Despite the delay, the United States — Food and Drug Administration has not raised concerns regarding the approvability of Lecanemab Iqlik as a starting dose. Lecanemab is a result of a collaboration between BioArctic and Eisai, with Eisai responsible for clinical development and commercialization.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard